Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
PHVS
Stock Latest News
Company Announcements
Pharvaris Announces Key Resolutions from Annual General Meeting
3d ago
6K
PHVS
Premium
The Fly
Pharvaris initiated with a Buy at Guggenheim on HAE potential
19d ago
PHVS
Premium
The Fly
Pharvaris initiated with a Buy at Guggenheim
20d ago
PHVS
Premium
Company Announcements
Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
20d ago
6K
PHVS
Premium
Ratings
Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
25d ago
PHVS
Premium
Ratings
Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
26d ago
PHVS
Premium
The Fly
Pharvaris presents data supporting ongoing clinical development of deucrictibant
28d ago
PHVS
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability
2M ago
PHVS
Premium
Ratings
Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target
2M ago
PHVS
Premium
The Fly
Pharvaris price target raised to $27 from $25 at Wedbush
2M ago
PHVS
Premium
The Fly
Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
2M ago
PHVS
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
2M ago
PHVS
Premium
The Fly
Pharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
2M ago
PHVS
Premium
Company Announcements
Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
2M ago
6K
PHVS
Premium
The Fly
Pharvaris initiated with an Overweight at Cantor Fitzgerald
2M ago
PHVS
Premium
The Fly
Pharvaris initiated with an Overweight at Cantor Fitzgerald
2M ago
PHVS
Premium
Ratings
Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
3M ago
PHVS
Premium
Ratings
Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
3M ago
PHVS
Premium
Ratings
Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
3M ago
PHVS
Premium
Company Announcements
Pharvaris Reports 2024 Financial Results and Business Progress
3M ago
PHVS
Premium
Ratings
Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion
3M ago
PHVS
Premium
The Fly
Trump threatens even higher tariffs on China after retaliation: Morning Buzz
3M ago
DG
GM
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.